drugset / Trial / NCT04925687
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa
Phase 1
Completed
4 enrolled
University of California, Davis
Cures Within Reach · collabThe Retina Society · collab
NaSingle-groupOpen-labelTreatment
Summary
In this Phase 1 open-labeled prospective study, one eye of each participant with vision loss from retinitis pigmentosa will be administered intravitreal injection of autologous CD34+ stem cells harvested from bone marrow. Each participant will be examined serially for 6 months after study injection to determine safety and feasibility of this intervention.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD34+ cells | Cell therapy | — | Intravitreal |